Baylor College Serves as Sequencing Center, Immunai, Boehringer Ingelheim Multi-Project Collaboration, Spatial Biology

Baylor College of Medicine’s Human Genome Sequencing Center was made the sequencing center for the new Population Genomic Screening Network (PGSN), an NIH-funded program piloting community-level testing for well-understood genetic conditions in a primary care setting. Baylor is expected to receive $9.9 million over five years from the National Human Genome Research Institute. Enrolled participants will receive genomic screening for hereditary breast cancer, ovarian cancer, Lynch syndrome, and inherited high cholesterol, as well as other conditions where early detection, intervention, and proven treatments can improve patient outcomes. The program will help determine best practices for effectively implementing genetic screening in primary care at the population level. Press release. 

Novogene Europe launched its Untargeted Metabolomics Service through its Cambridge Omics Centre. This new capability will help researchers across the U.K. and Europe to connect molecular data with biological function by adding metabolite-level insight to genomics, transcriptomics, microbiome, and broader life science studies. Built around Thermo Scientific Vanquish UHPLC coupled with Orbitrap Exploris 120 high-resolution accurate-mass mass spectrometry, the new liquid chromatography-mass spectrometry (LC-MS) workflow uses an extensive reference library, offering comprehensive, high-resolution metabolite profiling across suitable biological sample types. It complements Novogene Europe's established strengths in genomics, transcriptomics, sequencing, and bioinformatics, helping academic, biotech, and biopharma researchers move from molecular measurement toward deeper insight into disease mechanisms, microbiome interactions, treatment response, biomarker discovery, translational research, and pathway-level biology. Press release. 

Parhelia Biosciences and Sirona Dx announced a strategic partnership aimed at advancing the adoption of spatial biology in translational research, clinical trials, and precision health initiatives. While spatial biology technologies have transformed researchers' ability to understand tissue architecture and cellular interactions, many workflows remain highly manual, costly, and difficult to scale. This partnership will address these limitations. Sirona Dx brings extensive experience across a wide range of spatial biology technologies, enabling researchers to select and optimize the right platform and assay for each application. Parhelia contributes the Spatial Station, a configurable automation platform designed to standardize complex spatial biology workflows, reduce hands-on effort, and improve consistency across studies and sites. Press release. 

HanchorBio’s subsidiary, FBD Biologics Limited, has signed a strategic memorandum of understanding (MOU) with InxMed. This broadened the development path for HCB101, its lead oncology asset, through a new partnership with InxMed. Under the MOU, the two companies will conduct preclinical and translational research evaluating HCB101 in combination with InxMed's investigational assets, including IN10018/ifebemtinib, a FAK inhibitor, and OMTX705, a FAP-targeted antibody-drug conjugate. Press release. 

bit.bio launched two new cell culture media kits designed to make human cell-based research significantly more accessible and affordable for laboratories worldwide. Developed for use with bit.bio's human iPSC-derived ioGlutamatergic Neurons and ioMicroglia, the easy-to-use media kits remove one of the major practical barriers to adopting human cells by providing researchers with a simple, standardized, and cost-effective culture solution to make it easier for them to get started. Press release. 

Circular Genomics announced the launch of CircPATH, the company's proprietary circular RNA discovery and validation engine, following the publication of landmark findings in Nature Medicine demonstrating that blood-based circular RNA (circRNA) biomarkers can predict Alzheimer's disease progression with unprecedented accuracy. The study, led by Dr. Carlos Cruchaga at Washington University in St. Louis, represents the first demonstration that circRNAs can predict progression to symptomatic AD and outperform existing gold-standard biomarkers. CircPATH serves as the technological backbone powering all of Circular Genomics' future diagnostic product offerings, translating novel RNA biology into clinically actionable tools that promise to transform how neurodegenerative diseases are detected, monitored, and treated. Press release.  

Basecamp Research announced that its antibiotic design and vaccine target prediction EDEN models are now available through Claude, including Claude Science, Anthropic's AI workbench for life sciences research. This allows researchers to generate and prioritize therapeutic candidates through a conversational interface in a matter of minutes. By combining Claude's reasoning with EDEN's biological design capabilities, researchers can now go straight from a target to a shortlist of high-performing antibiotic or vaccine candidates. This capability is available in Claude.ai, Claude Desktop, Claude Mobile, Claude Code, Cowork, and Claude Science through Anthropic's connectors directory. Press release.  

Immunai and Boehringer Ingelheim have entered a multi-project collaboration to identify new T-cell targets in oncology and autoimmune diseases. Immunai’s single-cell AI platform will be used in detecting T-cell dysfunction patterns. Confirmed findings will then move to Immunai’s laboratory facilities, where they could serve as foundations for new portfolio projects within Boehringer Ingelheim’s drug discovery operations. T-cell dysfunction has a major role in the development of both cancer and autoimmune conditions, though research on these two disease areas has typically been separated. The collaboration aims to bridge this by using single-cell multiomic data and AI-driven functional validation to reveal biological mechanisms and targets that might not appear via more conventional or isolated research approaches. Press release.